Intramyocardial or intravenous injection of FGF23 in wild-type mice was shown to lead to LVH [29], whereas FGF23-induced LVH in patients with CKD might be independent of blood pressure, indicating differences in the cause of LVH between patients with cardiorenal syndrome and those without primary kidney damage [30]. This evidence concerns the gene FGF23 and chronic kidney disease.